Onglyza
(Saxagliptin)ApprovedSmall molecule
AstraZenecaSaxagliptin is used to help control blood sugar levels in people with type 2 diabetes. It works by helping the pancreas release insulin when blood sugar is high.[2] Onglyza is currently approved and in use across 19 indications[4].[1]
Onglyza is one of 411 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.
19
Indications
100
Total Trials
1
Active Trials
410
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
1
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 19 indications
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Onglyza
AstraZenecaApproved
Venclexta
AbbViePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
HLX10
Shanghai Henlius BiotechPhase 3
Platelet Rich Plasma
ZZagazig University
Phase 3
NTQ5082
NNanjing Chia-tai Tianqing Pharmaceutical
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes32 trials
Show 29 more trials
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
Completed·—·Phase 2·NCT02597101·14 enrolled
Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes
Unknown status·—·Phase 4·NCT02583438·100 enrolled
Metformin9 trials
Show 6 more trials
Type 2 Diabetes Mellitus6 trials
Safety and Efficacy4 trials
Show 1 more trial
Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient
Completed·—·Phase 4·NCT02182895·72 enrolled
Dapagliflozin3 trials
Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function
Completed·—·Phase 4·NCT02304081·64 enrolled
36 more indications
Function3 trials
Cystic Fibrosis2 trials
Oral2 trials
Efficacy and Safety2 trials
Type 1 Diabetes2 trials
Inflammation2 trials
Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation
Terminated·—·Phase 4·NCT01548651·8 enrolled
Lip2 trials
Tubular Markers in Response to Saxagliptin Therapy
Completed·—·Phase 4·NCT04521049·80 enrolled
Monotherapy1 trial
Diabetes1 trial
Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
Completed·—··NCT03936023·182,126 enrolled
Endothelial Dysfunction1 trial
LAM1 trial
Treatment1 trial
Combination Therapy1 trial
Autoimmune Diabetes1 trial
Coronary Artery Bypass1 trial
Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery
Terminated·—·Phase 4·NCT01765270·12 enrolled
Homeostasis1 trial
Drug1 trial
Cognitive Protective Effect of Newer Antidiabetic Drugs
Unknown status·—··NCT05347459·100 enrolled
Age1 trial
Concentration1 trial
Heart Failure1 trial
Drug Interactions1 trial
Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers
Unknown status·—·N/A·NCT04170790·18 enrolled
Cardiovascular Events1 trial
Type 2 Diabetic Patients1 trial
Diabetes Mellitus, Type 21 trial
Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
Recruiting·TThe University of Texas Health Science Center at San Antonio·Preclinical·NCT02969798·700 enrolled
Regulatory
FDA Approval Timeline[5]
Jul 31, 2009
ONGLYZA
NDA NDA022350
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Onglyza drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Saxagliptin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Nov 30, 2028
Earliest patent expiration — generic entry possible after this date
Patent #Expires
7951400Nov 30, 2028